TG Therapeutics Inc (TGTX)

TG Therapeutics Inc (TGTX) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $8.1B; returns 1 day +1.9%, 1 week +0.4%, 1 year +61.7%.

TG Therapeutics is a fully integrated commercial-stage biopharmaceutical company specialized in developing and commercializing novel treatments for B-cell mediated diseases. The company's economic engine is almost entirely driven by Briumvi (ublituximab-xiiy), a glycoengineered anti-CD20 monoclonal antibody approved for relapsing forms of multiple sclerosis (RMS). As of early 2026, U.S.

Groups TGTX belongs to

• Shrinking Share Count
• Biopharmaceutical
• Commercial Stage
• Commercial Stage Biotech
• Healthcare
• Biotechnology
• Monoclonal Antibodies
• Autoimmune Diseases
• Bispecific Antibodies
• Clinical Stage Biopharma

TGTX financial model: income statement, cash flow and balance sheet